Ownership and insider activity for Alaunos Therapeutics, Inc. (TCRT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Price
| Price | $1.28 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-06 | Weis Holger | A-Award | 4,363 | $9K |
| 2026-07-23 | Jerman Michael Allen | A-Award | 8,138 | $16K |
| 2026-07-23 | Weis Holger | A-Award | 4,568 | $9K |
| 2026-07-23 | Postma Robert W | A-Award | 8,463 | $16K |
| 2026-07-23 | Vieser Jaime | A-Award | 8,789 | $17K |
| 2026-06-30 | Weis Holger | A-Award | 3,880 | $9K |
| 2026-06-12 | Weis Holger | A-Award | 7,761 | $18K |
| 2026-05-22 | Weis Holger | A-Award | 3,700 | $9K |
| 2026-04-29 | Vieser Jaime | A-Award | 6,515 | $17K |
| 2026-04-29 | Postma Robert W | A-Award | 6,274 | $16K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $81.1M | $70.9M | $61.7M | $79.7M | $115.1M | $76.1M | $39.1M | $6.1M | $1.1M | $1.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $21000 | $19000 | $1.9M | $3.3M | $4.7M | $1.1M | $4000 | $1000 | $5000 | $3000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | $13.9M | 0 | 0 | 0 |
| Total Current Assets | $104.9M | $90.8M | $84.3M | $105.5M | $130.6M | $78.8M | $53.8M | $8.3M | $2.8M | $2.0M |
| Property, Plant & Equipment | $843000 | $1.2M | $1.1M | $3.4M | $14.9M | $15.4M | $10.6M | $2000 | 0 | $91000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $106.3M | $105.6M | $95.1M | $109.1M | $146.3M | $94.9M | $64.9M | $8.3M | $2.8M | $3.0M |
| Accounts Payable | $156000 | $4.4M | $707000 | $906000 | $960000 | $1.4M | $1.4M | $616000 | $516000 | $613000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | $8.6M | $17.3M | 0 | 0 | 0 |
| Total Current Liabilities | $15.8M | $20.9M | $9.5M | $12.5M | $18.4M | $16.0M | $24.2M | $2.0M | $692000 | $813000 |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $16.2M | 0 | 0 | 0 | 0 |
| Total Liabilities | $183.6M | $202.4M | $9.5M | $14.1M | $22.4M | $36.8M | $26.4M | $2.0M | $692000 | $813000 |
| Retained Earnings | -$658.0M | -$712.4M | -$566.3M | -$684.1M | -$764.1M | -$842.9M | -$880.6M | -$915.8M | -$920.4M | -$924.6M |
| Total Equity | -$77.3M | -$96.8M | $85.6M | $95.0M | $124.0M | $58.1M | $38.6M | $6.3M | $2.1M | $2.2M |
| Total Debt | 0 | 0 | 0 | $2.4M | $4.8M | $30.1M | $20.1M | 0 | 0 | 0 |
| Net Debt | -$81.1M | -$70.9M | -$61.7M | -$77.4M | -$110.3M | -$46.0M | -$19.0M | -$6.1M | -$1.1M | -$1.4M |
| Working Capital | $89.1M | $69.9M | $74.8M | $93.0M | $112.2M | $62.8M | $29.6M | $6.3M | $2.1M | $1.2M |
Financial Health
| Piotroski F-Score | 2 |
| Altman Z-Score | -436.02 |
Related companies: ADXN · AIM · CYCN · IBO · KTTA · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of TCRT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks